Next-Generation Biomarkers in Bladder Cancer: Urinary and Tissue Signatures

Abstract

Bladder cancer is among the most common malignancies of the urinary tract and remains a major contributor to global cancer-related morbidity and mortality. Despite advances in diagnosis and treatment, its high recurrence rate necessitates lifelong surveillance. Although cystoscopy and urine cytology remain the diagnostic cornerstone, their inherent limitations have driven the development of urinary and tissue biomarkers to improve early detection, surveillance, prognostic assessment, and prediction of treatment response. Several FDA- approved urinary biomarkers-including Nuclear Matrix Protein 22 (NMP22), Bladder Tumor Antigen (BTA), UroVysion Fluorescence in Situ Hybridization (FISH), and ImmunoCyt/uCyt+ immunofluorescence have demonstrated varying diagnostic performance. Simultaneously, advances in genomics, transcriptomics, proteomics, metabolomics, epigenetics, extracellular vesicles, and liquid biopsy technologies have considerably expanded the landscape of bladder cancer diagnostics. Furthermore, artificial intelligence-assisted biomarker integration represents an emerging frontier that may enhance precision diagnostics and individualized patient care. This narrative review comprehensively summarizes established and emerging urinary and tissue biomarkers in bladder cancer, critically evaluates their clinical utility and limitations, and discusses future directions toward precision medicine and personalized management in urothelial carcinoma.